<DOC>
	<DOCNO>NCT00701662</DOCNO>
	<brief_summary>The objective study ass efficacy , safety , convenience purify human antibody administer skin treatment MMN patient .</brief_summary>
	<brief_title>A Study Purified Human Antibodies Administered Subcutaneously Patients With Multifocal Motor Neuropathy ( MMN )</brief_title>
	<detailed_description />
	<mesh_term>Neuritis</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Patients document clinical diagnosis electrophysiological evidence MMN Patients previously respond intravenous immunoglobulin ( IVIG ) stable treatment IVIG least 12 week prior screen Patients treated equivalent â‰¥0.4g/kg body weight ( bw ) IVIG per month Provision inform consent patient Aspartate aminotransferase ( ASAT ) alanine aminotransferase ( ALAT ) concentration &gt; 2.5 time upper normal limit ( UNL ) Creatinine concentration &gt; 1.5 time UNL Known allergic reaction blood product Any skin disease interfere assessment injection site reaction Any medical condition , opinion investigator , might interfere successful completion protocol Any condition likely interfere evaluation study drug satisfactory conduct trial Participation study investigational drug within three month prior enrolment Patients treat equivalent &gt; 2.0g/kg bw IVIG per month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>